NasdaqCM - Delayed Quote USD

Vaccinex, Inc. (VCNX)

5.93 +0.93 (+18.62%)
At close: April 25 at 4:00 PM EDT
6.09 +0.16 (+2.68%)
After hours: April 25 at 7:59 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Maurice Zauderer Ph.D. Co-Founder, CEO, President & Director 411.7k -- 1947
Dr. Elizabeth E. Evans Ph.D. COO and Senior VP of Discovery & Translational Medicine 291.57k -- 1973
Dr. Ernest S. Smith Ph.D. Senior VP of Research & Chief Scientific Officer 297.25k -- 1972
Ms. Jill Sanchez CPA Chief Financial Officer -- -- 1972
Dr. John E. Leonard Ph.D. Senior Vice President of Development -- -- 1947

Vaccinex, Inc.

1895 Mount Hope Avenue
Rochester, NY 14620
United States
585 271 2700 https://www.vaccinex.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
37

Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its product Pepinemab is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Corporate Governance

Vaccinex, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
Vaccinex, Inc. Earnings Call

Related Tickers

VRAX Virax Biolabs Group Limited
0.7000
+7.53%
 
KTTA Pasithea Therapeutics Corp.
7.24
+3.43%
 
SABS SAB Biotherapeutics, Inc.
4.0100
-9.89%
 
RNAZ TransCode Therapeutics, Inc.
0.5250
+19.35%
 
SONN Sonnet BioTherapeutics Holdings, Inc.
1.7600
-2.76%
 
VRPX Virpax Pharmaceuticals, Inc.
2.9184
-5.55%
 
EDSA Edesa Biotech, Inc.
4.4684
+2.25%
 
CDT Conduit Pharmaceuticals Inc.
3.1000
-2.52%
 
NRBO NeuroBo Pharmaceuticals, Inc.
3.0600
-1.29%
 
IMNN Imunon, Inc.
1.4400
+10.77%